Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617762 | 0.86 | ALDH1A1 (0.32) | PGDALDH1A1 | |
| SCHEMBL7034290 | 0.86 | ALDH1A1 (0.32) | PGDALDH1A1 | |
| SCHEMBL1619271 | 0.83 | — | — | |
| SCHEMBL1619120 | 0.81 | — | — | |
| SCHEMBL1617804 | 0.79 | — | — | |
| SCHEMBL14256138 | 0.73 | PGD (0.32) | PGD | |
| SCHEMBL4514143 | 0.73 | PGD (0.32) | PGD | |
| SCHEMBL15330939 | 0.73 | PGD (0.32) | PGD | |
| SCHEMBL3730234 | 0.73 | PGD (0.32) | PGD | |
| SCHEMBL1619185 | 0.73 | CYP3A4 (0.31) | PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| EP-1472209-B1 | LIPOXIN A4 ANALOGS | BAYER SCHERING PHARMA AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-6831186-B2 | Antiinflammatory agents; autoimmune disease | SCHERING AKTIENGESELLSCHFT (DE) | 2004-12-14 | — | — | US | disclosed |
| US-20040162433-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | US | disclosed |
| US-20030139376-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTA4H | PGD 2067/4885ALDH1A1 1336/4885 |
| US-20040162433-A1 | Lipoxin A4 analogs | LTA4H, LTB4R, LTB4R2 | PGD 2952/4885ALDH1A1 1459/4885 |
| US-20030139376-A1 | Lipoxin A4 analogs | LTA4H, LTB4R, LTB4R2 | PGD 2952/4885ALDH1A1 1459/4885 |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTC4S | PGD 1662/4885ALDH1A1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.